Purpose of review Primary sclerosing cholangitis (PSC) is a rare, idiopathic biliary disease often with an insidious onset, variable disease course, and premature death related to benign and malignant PSC-related sequelae. This review aims to discuss the epidemiology, clinical variants, and natural history of PSC, incorporating data from recent population-based studies.
INTRODUCTION
Primary sclerosing cholangitis (PSC) is a rare biliary disease, often with an insidious onset and highly variable natural history. Up to about half of the patients may be asymptomatic at diagnosis and can remain stable for many years, whereas others present with end stage liver disease or advance relatively rapidly to liver failure [1, 2] or cholangiocarcinoma (CCA) [3,4 && ,5] . There is a significant association between PSC and inflammatory bowel disease (IBD) [5] [6] [7] [8] [9] , though considerable geographic variation has been reported [10] . Prior to the liver transplant era, death from liver failure was the leading outcome in PSC, but now it has been largely supplanted by liver transplant, and deaths because of CCA are relatively more common [4 && ]. In this review, we discuss the epidemiology, clinical variants, and natural history of PSC.
EPIDEMIOLOGY
North American and European prevalence and incidence of PSC range from 8.5 to 16.2 per 100 000 persons [7, 11, 12] , and 0.9-1.3 per 100 000 personyears, respectively [6, 7, 11, 12] . These studies come predominantly from specialized centers or small populations, which because of the rarity of the disease and referral bias may have resulted in inflated estimates of prevalence and incidence. A recent, larger population-based study of almost 8 million patients in the Netherlands found a lower prevalence and incidence rate of 6.0 per 100 000 persons and 0.5 per 100 000 person-years, respectively [4 && ]. Also, a near population-based data set in northern California found a similar prevalence and incidence of 4.03 per 100 000 persons and 0.41 per 100 000 person-years, respectively [5] . Lastly, United Kingdom's General Practice Research Database estimated the prevalence and incidence at 3.85 per 100 000 and 0.41 per 100 000 person-years, respectively [13] . When examined over time, there has been a slow but significant increase in the prevalence of PSC cases [4 && ,7,11,13] . One study reported an increase in average annual percentage change of 3.06 [11] ; in addition to reflecting an actual increase in incidence, this change may be because of improved survival, increased diagnosis because of increased disease awareness, increased testing of liver biochemistries, and/or increased use of MRI.
In nonwhite populations, transplant data suggest that African-Americans are affected with PSC at rates similar to whites, but tend to be younger and have higher model for end-stage liver disease scores at the time of listing for liver transplantation compared with whites and Hispanics, suggesting a more severe disease phenotype [14] . In contrast, in Alaskan natives, PSC was not found in a large study of liver disease patients [15] , and in Japan and Singapore, limited data suggest that PSC is rare in East Asia [16, 17] .
DIAGNOSIS
According to the American Association for the Study of Liver Diseases, PSC is diagnosed in a patient with cholestatic laboratory values, bile ducts with multifocal strictures, and segmental dilations on magnetic resonance cholangiopancreatography (MRCP) or endoscopic retrograde cholangiopancreatography (ERCP), and when secondary causes of sclerosing cholangitis are excluded [18] . MRCP has a sensitivity and specificity of 80 and 87%, respectively, and ERCP has a sensitivity and specificity of 89 and 80%, respectively [19] . MRCP is preferentially utilized for diagnosis to avoid the potential complications of ERCP, whereas ERCP can facilitate therapeutic intervention and biliary specimen acquisition during the procedure [20,21 & ].
Liver biopsy is seldom used because of its low diagnostic value [20, 22] . Indeed, the pathognomonic periductal fibrosis ('onion skinning') is only seen in 14% of patients [22] . It should be noted that serum liver tests may spontaneously normalize in up to 20% of patients with PSC, and in rare instances, may be normal at the time of diagnosis [23] .
CLINICAL VARIATION IN PRIMARY SCLEROSING CHOLANGITIS
The heterogeneity of PSC has become increasingly apparent with attempts to group patients into variants of PSC based upon clinical features. Whether these variants represent different pathogenic processes leading to similar outcomes or different manifestations of the same disease remains unclear. Although numerous variants have been described based upon sex, IBD presence or type, race, age of onset, serum alkaline phosphatase levels, and the presence of elevated serum IgG4 levels, the major differences among these variants are limited to the effects of the disease on the liver. Namely, whether large ducts or small ducts are primarily affected and if there is significant, concomitant hepatocyte injury, that is overlap with autoimmune hepatitis (AIH). The diagnosis of PSC is generally based upon the presence of segmental intrahepatic and/or extrahepatic biliary strictures on cholangiogram in the absence of a secondary cause, such as malignancy, ischemia, trauma, or infection. The median age at diagnosis of PSC is between 30 and 40 years [5, 6, 9] but can affect people of all ages; 7% of patients are diagnosed under the age of 18, 30% are diagnosed from 18 to 35 years, 50% are diagnosed from 36 to 65 years, and 13% are diagnosed at over 65 years [5] . Unlike most autoimmune diseases, there is a striking male predominance with the disease twice as prevalent in men than women [5] [6] [7] 9, 11] .
In the classic form of PSC, multifocal biliary strictures and dilation are present on cholangiogram and has come to be known as large-duct PSC. In contrast, small-duct PSC is diagnosed when the characteristic bile duct changes are absent on imaging, but liver biopsy shows characteristic biliary (periductal) fibrosis with a cholestatic serum biochemical profile [18] . Compared with large-duct PSC, small-duct PSC is similar in male predominance and age at diagnosis [24] but is one-fifth as frequent with an incidence of 0.15 per 100 000 person-years [6] . Importantly, small-duct PSC patients have a favorable prognosis [4 && ], although some patients with small-duct PSC progress to largeduct PSC [25] . The more favorable prognosis is in part because of these patients having a lower rate of developing CCA compared with large-duct PSC [25] .
KEY POINTS PSC is a rare disease with a significant association with IBD, a rising incidence rate, a variable natural history, and a transplant-free survival of roughly 20 years.
Variations in PSC exist and may be an important distinction to make for prognostication, clinical management, and disease-oriented research.
Complications of PSC include cirrhosis and liver failure, CCA, other hepatobiliary cancer, dominant strictures, bacterial cholangitis, and hepatic osteodystrophy.
In all, 4-14% of patients with PSC will have overlapping AIH [4 && ,6,26] . There remains controversy and a lack of consensus on the criteria that should be used to define PSC-AIH overlap, which may appear simultaneously or PSC may appear following a diagnosis of AIH. The distinction between PSC-AIH and PSC without AIH is important to make as the former may benefit from immunosuppression [27, 28] . Another important, but often difficult, distinction is among a subset of patients with elevated IgG4. IgG4-related cholangiopathy can present with cholangiographic abnormalities similar to PSC, but is a distinct entity that is responsive to corticosteroids and other immunosuppressants. In contrast, elevated IgG4 levels can be found in roughly 10% of PSC [29, 30] , but whether IgG4 alters disease course in PSC is unclear [29] .
Importantly, PSC is found in association with IBD in 60-80% of cases, with a higher prevalence of IBD among men compared with women with PSC [3, [5] [6] [7] [8] [9] 31 & ]. In roughly 70% of PSC-IBD patients, clinical recognition of IBD will precede the diagnosis of PSC by several years, whereas 10% of patients are diagnosed with PSC and IBD concurrently [7, 32] . Over time, the frequency of IBD has been decreasing in PSC, which may reflect an increase in clinicians regarding PSC as a disease that can occur without the intestinal disease [33] . Approximately 70-80% of the IBD associated with PSC are diagnosed as ulcerative colitis, whereas the remainder are Crohn's disease or indeterminate colitis [9, 31 & ]. Notably, the Crohn's disease tends to present with colitis and rarely has a fibrostenosing phenotype. In fact, the IBD associated with PSC (PSC-IBD) in many cases has a unique phenotype with pancolitis or colitis restricted to the right side and a tendency for rectal sparing and backwash ileitis [34] . Of note, women with PSC tend to have lower rates of IBD than men (61.4 vs. 82.4%), with Crohn's disease being proportionately more common in women [11] . Conversely, PSC can be found in up to 8% of IBD patients [35 && ] with risk factors for PSC, including male sex, nonsmoker status, pancolitis, and appendectomy [36] . This prevalence was found after screening patients with 20 or more years of IBD with magnetic resonance cholangiography. This is a significant increase from the roughly 2% prevalence of PSC found in the Swiss Inflammatory Bowel Disease Cohort Study population [36] and may reflect an early or milder form of the disease, further complicating the study of PSC natural history. Although IBD alone increases the risk of colorectal carcinoma (CRC), a recent meta-analysis found that IBD with PSC had an increased risk for CRC (odds ratio of 3.24) and presented at a younger age compared with IBD patients without PSC [ 
NATURAL HISTORY
PSC follows a variable natural history (Fig. 1) . Initially, 10-60% of patients are asymptomatic and may be diagnosed with PSC incidentally because of abnormal liver biochemistries [1, 6, 9, 32] . Elevated alkaline phosphatase is the most common serum abnormality, although transaminases as well as gglutamyl transferase are often elevated as well [18] . Bilirubin is normal initially in most cases, but like other serum liver test values, can fluctuate throughout the disease course. The elevated laboratory values may decrease after the diagnosis, as one study with over 300 patients showed that the average alkaline phosphatase, aspartate transaminase, alanine transaminase, and total bilirubin decreased from 1.99, 1.45, 2.11, 0.81 Â the upper limit of normal to 1.22, 0.88, 1.00, and 0.65 Â the upper limits of normal in 1 year [26] . In fact, up to 40% of patients may experience normalized alkaline phosphatase levels in 1 year, and these patients have a higher rate of liver transplant-free survival [26, 38] . Hepatomegaly and splenomegaly are present in 43.6 and 29.3% of patients, respectively, at presentation [9] . A small subset of patients is diagnosed in the late stages of PSC with cirrhosis and ascites [6] . When symptoms of PSC develop, abdominal pain, pruritus, diarrhea, jaundice, fatigue, and fever are most common [6, 9, 24] . The disease may eventually lead to cirrhosis with portal hypertension, ascites, esophageal varices, and liver failure in a similar fashion as other chronic liver disease [3, 7, 18] . Clinicians can follow platelet levels, as platelets less than 150 Â 10 3 /dl have an odds ratio of 6.3 for esophageal varices [39] , among other clinical parameters (e.g., splenomegaly on imaging), which may herald the onset of portal hypertension and its sequelae.
Before the 1990s, the majority of PSC patients died from PSC/liver-related complications; however, in the past 25 years, liver transplantation has largely supplanted these outcomes. Unfortunately, the proportion of patients dying from CCA has changed minimally (Fig. 2 [4 && ,5,9,33,40-49]). In one study, patients with PSC were found to carry a four-fold increased risk of mortality than the general population and the most frequent cause of deaths was CCA (32%), liver failure (18%), liver transplant complication (9%), and CRC (8%) [4 && ]. The annual incidence of CCA, which often occurs ], although a significant portion of these are diagnosed within the first year of PSC diagnosis [9, 44, 50] . In all, 80% of patients who develop CCA die within 1 year [4 && ]. Additionally, the annual incidence rate of CRC in PSC patients is less than 0.5%, with a 30-year cumulative risk of 13%. Significantly, only 16% of patients who received an annual to biannual surveillance colonoscopy died from CRC compared with 50% of those who did not [4 && ]. Other causes of death include hepatocellular carcinoma, gallbladder carcinoma, pancreatic cancer, and nonmalignant disease [5, 32, 50] .
Early estimates of median time from diagnosis to death or liver transplant were 9.6-18 years [9, 24, 45] . However, these studies were performed at centers specializing in PSC, which likely led to recruitment bias of more severe cases. A more recent populationbased study from the Netherlands found a median transplant-free survival of 21.3 years among patients at nontransplant centers compared with 13.2 years among PSC patients at transplant centers [4 && ]. Thus, survival of patients with PSC is believed to be longer than initially perceived, an observation which may be related to transplant center referral bias in earlier studies and improved overall management of patients with chronic liver disease.
In summary, patients with PSC can have varying presentation from being asymptomatic to having symptoms of liver failure, exhibit variable serum liver chemistry values throughout the disease course, and progress at differing rates to need for liver transplant or death. In the absence of liver transplant, median survival is now estimated at 20 years; whereas some patients will present with advanced fibrotic or malignant disease, others will experience prolonged survival, whereas yet some others will not experience major adverse outcomes because of PSC during their lifetime.
NONMALIGNANT COMPLICATIONS IN PRIMARY SCLEROSING CHOLANGITIS
In addition to transplant-free survival, other important clinical events occur as part of the natural history of PSC, which greatly impact the lives of patients with PSC and in some cases may lead to fatal complications.
DOMINANT STRICTURES
Dominant strictures are defined as a 1.5 mm or less stenosis of the common bile duct and/or 1.0 mm or less stenosis of hepatic duct within 2 cm of the bifurcation of the left and right hepatic ducts [51] . Dominant strictures occur in 45-63% of PSC patients over the course of disease and patients with elevation of serum bilirubin, worsening pruritus, increased dilatation of bile duct, and cholangitis should undergo examination [18, [52] [53] [54] . Within patients with dominant strictures, Candida in bile appears to be associated with worse survival [53] . Dominant stricture has a poor prognosis and should raise suspicion of CCA [9, 18] . In fact, patients with dominant strictures have a much worse survival rate than those without dominant strictures (13.7 vs. 23.0 years), and the difference was significantly reduced when patients with CCA were excluded from those with benign dominant strictures (17.5 vs. 23.0 years) [54] .
BACTERIAL CHOLANGITIS
In roughly 6% of patients, ascending cholangitis is present during the initial diagnosis of PSC. After PSC diagnosis, detecting acute cholangitis can be difficult as patients with PSC often already have abnormal serum liver tests and abdominal pain [6] . Acute cholangitis should be suspected in patients who have an abrupt development of or worsening in these parameters and/or develop otherwise unexplained fever or leukocytosis. Although epidemiologic data regarding acute cholangitis in PSC are limited, in a cohort of PSC patients undergoing liver transplant, 38.6% had a history of bacterial cholangitis and 28% had acute bacterial cholangitis while on the waitlist. Of note, though, having a history of bacterial cholangitis did not alter waitlist survival significantly, and no waitlist patients died because of bacterial cholangitis over a study period of roughly 10 years [3] .
HEPATIC OSTEODYSTROPHY
Bone loss is common in cholestatic liver diseases and can occur even in young men (an otherwise low-risk group) with PSC. When measured by dualenergy X-ray absorptiometry in patients, the risk of osteoporosis is increased 23.8-fold in PSC, with additional risk factors, including age more than 54 years, BMI less than 24 kg/m 2 , and IBD duration more than 19 years [55] . The rate of bone loss has been estimated to be 1% per year and does not appear to be affected by treatment with vitamin D and calcium supplements, hormone replacement, or corticosteroids. CONCLUSION PSC is a rare disease with heterogeneous clinical features and a highly variable natural history. Indeed, given the variables of age, race, IBD, stricture location and degree, AIH overlap, and IgG4, there are in essence over 3000 possible different combinations of PSC phenotypes [56 & ]. Overall, average liver transplant-free survival remains 15-20 years, and CCA remains a leading cause of death. A better understanding of distinct subsets of PSC may provide important insights into the disease and lead to novel therapies and better management strategies. With the recent increase in PSC incidence, we hope that awareness of the disease will similarly increase to accelerate research developments and improve patient care.
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